In the phase 2/3 study IL-6 was shown to be both prognostic as well as predictive for Nap activity since the subgroup and a trend analysis clearly supported that low baseline anti-SEA/E-120 and IL-6 plasma levels independently predict anti-tumour efficacy after Nap+IFN-α treatment. The gene discussed is IL6; the disease is neoplasm.